Abstract: An intrauterine device includes a central support member, first and second internal flexures and first and second external flexures. The first and second internal flexures each include a first section having a first stiffness, a second section having a second stiffness, and third section having a third stiffness, wherein the second stiffness is more flexible than the first and third stiffness and wherein the first section of each internal flexure is coupled to the central support member. The first and second external flexures are coupled to the central support member and coupled to the third sections of the first and second internal flexures, the first and second external flexures in combination with the first and second internal flexures being configured to extend from a collapsed position parallel to the central support member to a deployed position flexing away from the central support member.

Abstract: A flexible device having a layered structure for delivering light or ultrasound to a skin surface. The device includes a flexible substrate that supports either a flexible light emitter layer or a flexible ultrasound emitter layer, as well as first and second flexible conductive layers. The device has a surface configured to face the skin surface, wherein (a) the light emitter layer emits pulsed light with an intensity that is substantially constant across the device's surface when driven by a power source connected to the conductive layers to thereby deliver a therapeutically effective dose of pulsed light to the skin surface or (b) the ultrasound emitter layer emits ultrasound with an intensity that is substantially constant across the device's surface when driven by a power source connected to the conductive layers to thereby deliver a therapeutically effective dose of ultrasound to the skin surface.

Abstract: Wearable heat transfer devices and associated systems and methods are disclosed herein. In some embodiments, a representative heat transfer device can comprise (i) a thermoelectric component (TEC) including a first side configured to be operated at a desired temperature and a second side opposite the first side, (ii) a thermally conductive contact member thermally coupled to the TEC, and (iii) a heat transfer system configured to distribute heat from the TEC. The heat transfer system includes a heat transfer structure thermally coupled to the TEC, and a heat exchanger thermally coupled to the heat transfer structure.

Abstract: A macular indentor for implantation on an eye of a patient includes a curved backbone extending from a first end to a second end and a raised pad coupled to the first end of the backbone. The raised pad extends inward from an inner face of the backbone such that, when the macular indentor is implanted on the eye, the raised pad applies pressure to the sclera of the eye which contacts the macula of the eye. The geometry of the backbone is configured to match the geometry of the eye.

Abstract: The present disclosure generally relates to a fluid-driven vitrector for vitreo-retinal procedures. The vitrector includes a first fluid pathway containing a first fluid and a second fluid pathway containing a second fluid that are completely sealed from an external environment. Because the fluid pathways are completely sealed from an external environment, an alternative fluid that can transmit pressure waves faster than air may be utilized as the first and second fluids to drive the vitrector.

Abstract: In some embodiments, a vitrectomy probe may include an inner cutting tube reciprocating in an outer tube. The outer tube includes a side port and the inner tube includes a distal cutting port, and, in some embodiments, an additional side port. In some embodiments, the inner tube may also include a flat upper edge that cuts across the outer tube side port. In some embodiments, a diaphragm drives the inner tube and may have an open-stroke side with a lower hardness material than a closed-stroke side. In some embodiments, an aspiration tube coupled to the vitrectomy probe may include a first aspiration tubing and a second aspiration tubing with a lower hardness than the first aspiration tubing. In some embodiments, the vitrectomy probe may be coupled to pneumatic tubing that is stepped or tapered.

Abstract: Goggles and eyewear with various features are described herein. Such goggles and eyewear may include lenses that allow for the installation of larger roll-off films, adjustable nose sections to increase comfort of a wearer, sweat management systems that include a permeable gasket and a gutter, lens attachment systems, and co-molded frames of multiple different materials.

Abstract: According to an embodiment of the present disclosure, provided is a welding protector including a head band including a band main body including a front support portion for supporting forehead of a user, a rear band portion arranged opposite to the band main body, and a support band portion connected to the front support portion and supporting an upper portion of the user's head, a face shield rotatably connected to the head band and protecting face of the user, and an auxiliary shield protecting a part of the user's head, wherein the auxiliary shield and the head band are connected to each other.

Abstract: A stretcher with a heated section, the heated section of the stretcher comprising: two opposing electrically conductive elements positioned at, or towards, opposing sides of the stretcher, wherein the opposing electrically conductive elements are connectable to a power source; an electrically conductive layer in electrical contact with the opposing electrically conductive elements, to heat up when the opposing electrically conductive elements are powered by the power source; such that the electrically conductive layer is X-ray transparent to allow a patient to be X-rayed whilst on the stretcher.

Abstract: An enclosed patient suite may include a plurality of suite walls, a patient bed positioned in a patient area defined within the plurality of suite walls, a plurality of medical systems with at least some of the plurality of medical systems mounted to the plurality of suite walls, a plurality of support members coupled to the plurality of suite walls, a plurality of wheels with a particular wheel of the plurality of wheels coupled to a corresponding support member of the plurality of support members, a rail brake configured to engage a floor-mounted rail in a floor of at least one of a cargo hold or a cabin of an aircraft, and a controller coupled to the plurality of medical systems and configured to receive data from and transmit data to the plurality of medical systems. The enclosed patient suite may be dimensioned to fit within the aircraft.

Abstract: An neonatal care unit comprising: a hood defining an interior space and having a bottom opening, wherein the hood is dimensioned to accommodate a neonate; a sealing skirt extending along at least a portion of a peripheral edge of the bottom opening and configured to engage at least part of a front torso region of a human in a sealing engagement; at least one access opening located about a sidewall of the hood and dimensioned to allow passage of the neonate therethrough; at least two arm ports located about the sidewall and dimensioned to allow passage of a hand therethrough; and at least one port configured to allow passage of a medical conduit therethrough.

Abstract: An upgrade system upgrades a motorized mobile chair to a smart motorized mobile chair. The motorized mobile chair has a processing system comprising at least two processors. The upgrade system comprises a plurality of object detection sensors and at least one processing unit connected between at least a first one of the at least two processors of the processing system and at least a second one of the at least two processors of the processing system. The processing unit receives sensor data from at least one of the plurality of object detection sensors, receives at least one control signal transmitted from the first processor, the control signal comprising data, modifies or does not modify the data of the control signal based on at least the sensor data, and transmits the modified or not modified control signal, the transmitted control signal to be received by the second processor.

Abstract: An adjusting device for vehicles comprising at least one mounting plate and one support plate with a lifting device comprising at least two scissor mountings. The scissor mountings are each arranged at the longitudinal side edge or in a corner region of the mounting or support plate and are vertically adjustable via a drive unit. Each scissor mounting takes the form of double scissors and includes a first, lower scissor element and a second, upper scissor element which are connected to each other at one end via a common rotation pin. The lower scissor element is connected at the other end to the mounting plate, and the upper scissor element is connected at the other end to the support plate via fasteners.

Abstract: A knee joint stimulation device that can effectively stimulate a knee joint is composed of a base, a frame provided upright on the base, a center shaft provided at an upper part of the frame, a crank connecting a motor and the center shaft and driven by rotation of the motor, a swing arm hanging down perpendicularly from the center shaft, and a support plate unit provided at a lower end of the swing arm and allowing a user in a sitting position to put his/her sole thereon. With the user putting the sole on the support plate unit, the length of the swing arm is adjusted such that a pivot point of a knee joint of the user is aligned with the center shaft.

Abstract: A motorized tensioning mechanism for orthotic devices, such as a knee brace, wherein the controls for the motorized tensioning mechanism may be manual, automatic, or a hybrid of both. Sensors associated with the orthotic device may inform the user regarding tension or other aspects of the device, and, in cases, may automatically adjust tension in the motorized tensioning mechanism.

Abstract: A mobility assistance apparatus includes first and second frames positioned on left and right sides of a user; a hinge arm mechanism coupled to the first and second frames; and a securing unit or a walking seat coupled to the frames to transfer at least a portion of the user's body weight from the legs and to transfer weight through the user's hip or pelvis to the first and second frame enabling the user to stand or work for an extended period without requiring the user's arms to hold the frame.

Abstract: A method and/or device for treatment of dysregulated reduced blood (e.g., reduced ocular blood flow) and, more particularly, but not exclusively, to methods and/or devices for treatment retinal, choroidal and optic nerve disorders. The treatment includes application of an effective amount of ONS ophthalmic nerve stimulation alone and/or in combination with peri-ocular administration of substance Neuropeptides/Platelet Rich Plasma (N/PRP) and/or ascorbic acid as a sympatholytic agent.

Abstract: A device for organizing and tracking medication. The device includes compartments to contain medication, and each compartment includes an access door. A sensor element can detect if the device is moved, if the access door is opened and/or closed, and/or if medications have been placed into or removed from a compartment. A processor and/or external computing system provides alarms if medications is not properly taken, a filling service for stuffing the compartments and an administration service to verify the medications are properly taken.

Abstract: A charge device is provided that includes a charge barrel having a charge. The charge barrel has an exit aperture and a flexible positioning device at the exit aperture. The charge is located inside the charge barrel. The charge barrel is adapted and arranged so that the charge is able to exit the charge barrel via the exit aperture.

Abstract: A supple carrier for carrying a container of medically useful solution or suspension. The supple carrier includes a first monitoring window providing a first visualization perspective of the container contained by the envelope and one or more adjustable pressurizers. The supple carrier can delay the temperature change of the medically useful solution or suspension carried by the carrier.

Abstract: The invention provides for a delivery system including a delivery assembly configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient.

Abstract: A nasogastric tube stabilization system is provided. The nasogastric tube stabilization clip includes a clip operatively associated between the first portion and the second portion of nasogastric tube stabilization adhesive, wherein the clip is movable between a clipped condition and an unclipped condition, enabling the first and second portions of nasogastric tube stabilization adhesive to move independently of each other for facilitating treatment of a patient, wherein the nasogastric tube stabilization adhesive portions adhere to a nasogastric tube and the nose of patient, respectively, thereby in the clipped condition the nasogastric tube stabilization system stabilizes the nasogastric tube relative to the patient.

Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Abstract: An injectable medication tab used to track expiration dates has an informative tab, a release string, an adhesive liner, and a quick release fastener. The informative tab provides visually accessible information about a bottle to which the injectable medication tab is attached. An expiration information portion of the informative tab protrudes from the exterior surface of the bottle after being opened. The adhesive liner is superimposed onto a mounting surface of the informative tab and attaches the informative tab to the bottle. The quick release fastener is a coupling mechanism that connects between an edge of the informative tab and the release string. The release string forms a detachable connection holding the expiration information portion against the bottle until the bottle is opened. Once opened, the expiration information section to protrudes from the bottle until the expiration information is recorded and the medical information portion is adhered to the bottle.

Abstract: The present disclosure relates to topical compositions and methods for the treatment of radiation dermatitis. The compositions include specific formulations of a cannabinoid and olive oil, along with other specified ingredients.

Abstract: The present invention relates to methods and uses of compositions comprising curcumin; in particular, methods and uses relating to improving the bioaccessibility, bioavailability, bioefficacy and/or bioactivity of curcuminoids in mammals.

Abstract: An antiseptic solution comprising a pH-dependent antimicrobial agent, the pH-dependent antimicrobial agent having an operative pH range, wherein the solution has a pH on storage that is lower than the operative pH range. Applicators for applying the antiseptic solution and methods of using the antiseptic solution and applicators are also provided.

Abstract: A method for manufacturing the mechanoreception fabric for incorporation into a garment or item of apparel sets a liquid substrate to a fabric weave to produce a plurality of protuberances in graticulate array and spaced apart across a surface of the fabric. The plurality of protuberances includes pyramidal nodes, each independent and separate from other nodes, not less than 1 mm apart at the base and not more than 5 mm apart at each apex and 1.5 mm in height. Because the nodes are separated and not in contact with each other, the fabric produced is still stretchable and wearable when incorporated into an item of apparel despite the nodes having a hardness of between Shore A 60 and 80.

Abstract: The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.

Abstract: Nutritional compositions contain a mixture of ketogenic ingredients including from 80 to 99% weight % 1,3-butanediol (BDO), preferably R-1,3-butanediol, and from 1 to 20 weight % beta-hydroxybutyric acid (BHB), preferably D-beta-hydroxybutyric acid, or an equivalent molar amount of its conjugate base beta-hydroxybutyrate, salts, monoesters, polyesters, or mixtures thereof. In some embodiments, the nutritional compositions for providing ketosis are prepared for oral administration in a solid form, such as bars, bites, tablets, pills or capsules, in a liquid form, such as smoothies, goos, water, carbonated beverages, soft drinks, fermented beverage suspensions, solutions and emulsions, or in a powder form that can be used to prepare drink mixes or can be added as a supplement to other food or drink products. Methods of providing ketosis in a subject include delivering optimal therapeutic ketosis, with rapidity into and extended duration of blood concentrations of D-BHB of between 1 mM and 2.5 mM.

Abstract: Disclosed herein is a method for alleviating a kidney disease or fibrosis of an organ in a subject, which includes administering to the subject a composition containing a ferrous amino acid chelate which includes ferrous ions and an amino acid.

Abstract: Provided is a medical compound including a synthetic flavone derivative, according to the formula (I) with allotment in position C-3 of a group as shown below: wherein at least two of R2-R6 are H, and the remaining are independently selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.

Abstract: There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

Abstract: The invention provides the use of SWELL1 inhibitors and modulators for therapeutic use, e.g., to treat obesity and type 2 diabetes.

Abstract: The invention relates to the alkaloids mesembranol or mesembrenol, or pharmaceutical acceptable salts or complexes thereof, for use in the prophylaxis or treatment of a disease that responds to treatment with an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist. The prophylaxis or treatment attenuates AMPA mediated neurotransmission in the hippocampus of a subject.

Abstract: An 5-(4,5-bis(4-chlorophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)pentanoic compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.

Abstract: The present disclosure provides endosomal disruptors, which are useful for facilitating delivery of a macromolecule to the cytoplasm of a cell. The present disclosure provides compositions comprising an endosomal disruptor and a macromolecule. The present disclosure provides methods of delivering a macromolecule to the cytoplasm of a cell.

Abstract: The invention relates to the treatment of cognitive impairment associated with schizophrenia (CIAS) with a specific GlyT1 inhibitor ([5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone). A 12-week treatment in a phase 2 study showed improvement in cognitive function as measured by the MATRICS Consensus Cognitive Battery (MCCB) overall composite score.

Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl] acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25 C is disclosed.

Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.

Abstract: One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.

Abstract: The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.

Abstract: Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.

Abstract: Disclosed are combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake promoting activity.

Abstract: A method of treatment of a patient suffering from autonomic dysfunction is described. The method of treatment can include the steps of initially evaluating the patient and administering buprenorphine to treat the patient, for example, daily. The patient undergoing such treatment is subjected to monitoring. The monitoring of the patient may be on a periodic basis, for example, a weekly basis, a daily basis, or on a real-time basis. Such monitoring may be through any one or combination of a plurality of bodily measurements that includes, for example, heart rate variability or blood catecholamine concentrations. Monitoring of the patient may also occur remotely. Methods are also described for determining whether the amount of buprenorphine provided to the patient may be tapered.

Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.